@article{ffbd6fd68ee5405a98261147915c2ce5,
title = "Discovery and mechanisms of host defense to oncogenesis: targeting the β-defensin-1 peptide as a natural tumor inhibitor",
abstract = "Human beta-defensin-1 (hBD-1) is one of a number of small cationic host-defense peptides. Besides its well-known broad-spectrum antimicrobial function, hBD-1 has recently been identified as a chromosome 8p tumor-suppressor gene. The role of hBD-1 in modulating the host immune response to oncogenesis, associated with cell signaling and potential therapeutic applications, has become increasingly appreciated over time. In this study, multiple approaches were used to illustrate hBD-1 anti-tumor activities. Results demonstrate that hBD-1 peptide alters human epidermal growth factor receptor 2 (HER2) signal transduction and represses retroviral-mediated transgene expression in cancer cells. Loss of orthologous murine defense-1 (mBD1) in mice enhances nickel sulfate-induced leiomyosarcoma and causes mouse kidney cells to exhibit increased susceptibility to HPV-16 E6/7-induced neoplastic transformation. Furthermore, for the first time, a novel function of the urine-derived hBD-1 peptide was discovered to suppress bladder cancer growth and this may lead to future applications in the treatment of malignancy.",
keywords = "bladder cancer, gene expression, HER2, Host defense, human defensins, tumor inhibitors, tumor therapeutics, tumor-associated macrophages (TAMs)",
author = "Sun, {Carrie Q.} and Arnold, {Rebecca S.} and Hsieh, {Chia Ling} and Dorin, {Julia R.} and Fei Lian and Zhenghong Li and Petros, {John A.}",
note = "Funding Information: This work was supported by the Emory University Urology Department and the Medical Research Council, UK. Funding Information: We thank Dr. Thomas Ganz, Dr. Erika V. Valore, Dr. Lily Yang, Dr. Guan-Zhe Wu, and Dr. Jack Arbiser for the generous gifts of hBD-1 antibody, BT474 breast cancer cells, TSU-Pr1 bladder cancer cells, nickel sulfate compound, and unlimited technical support. This study was supported by JRD funded by Medical Research Council UK. Funding Information: This work was supported by the Emory University Urology Department and the Medical Research Council, UK. We thank Dr. Thomas Ganz, Dr. Erika V. Valore, Dr. Lily Yang, Dr. Guan-Zhe Wu, and Dr. Jack Arbiser for the generous gifts of hBD-1 antibody, BT474 breast cancer cells, TSU-Pr1 bladder cancer cells, nickel sulfate compound, and unlimited technical support. This study was supported by JRD funded by Medical Research Council UK. Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.",
year = "2019",
month = jun,
day = "3",
doi = "10.1080/15384047.2018.1564564",
language = "English",
volume = "20",
pages = "774--786",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "6",
}